GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The company announced positive topline data from the Phase II ZUPREME-1 trial
Subscribe To Our Newsletter & Stay Updated
